BYOND (B1871039) = Safety and Efficacy of Bosutinib in Ph+ CML Previously Treated with TKI
Study title
Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors [Europe, USA]
Scientific title
A Phase 4 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors (EudraCT Number 2013-003250-25; Clinicaltrials.gov No. NCT02228382)
Type of study
Other trials
In multiple countries
Current status
Study enrollment is closed
What is the purpose of the study
This study evaluates the safety and efficacy of bosutinib in patients with Ph+ CML previously treated with one or more tyrosine kinase inhibitors. It includes 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (after treatment with at least three other tyrosine kinase inhibitors).
Bosutinib will be administered at 500 mg once a day for up to 4 years.
Key inclusion criteria
To be considered for inclusion in this study patients must have confirmed Philadelphia Chromosome positive Chronic Myelogenous Leukemia (Ph+ CML) or confirmed BCR-ABL1 if Philadelphia Chromosome negative Chronic Myelogenous Leukemia (Ph- CML) from initial diagnosis.
They have previously been treated with one or more tyrosine kinase inhibitor (TKI) drugs (imatinib, dasatinib and/or nilotinib) for Philadelphia Chromosome positive CML. CML may be in any phase, as long as the patient is unable to receive treatment with imatinib, dasatinib and/or nilotinib for any reason.
Patients must be 18 years or older and have adequate bone marrow, liver and kidney functions.
They should have an ECOG of 0-1 if in Chronic Phase or of 0-3 if they are treated fourth line (and beyond) in Chronic Phase or if they are in Accelerated Phase or Blast Phase.
Key exclusion criteria
Where can I find additional information
Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health
Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)
Study sponsor
Pfizer
Scientific lead / contact
Jocelyn Leone
Principal investigator
Prof. Andreas Hochhaus
Universitätsklinikum Jena, Germany
Study centers / principal investigators
Austria
Innsbruck
Universitaet Innsbruck
Linz
Hospital “Barmherzige Schwestern”
Internal Medicine I
Belgium
Antwerpen
Ziekenhuis Netwerk Antwerpen
France
Bordeaux
Institut Bergonie
Bordeaux Cedex 09
Le Chesnay Cedex
Centre Hospitalier de Versailles Hopital Andre Mignot
Marseille
Centre Regional De Lutte Contre Le Cancer
Nice
Nice Hopital Archet 1
Service Hematologie clinic
Nice Cedex 3
Toulouse cedex 9
IUCT – ONCOPOLE
Toulouse cedex 9
Vandoeuvre-les-Nancy
CHU Brabois
Germany
Aachen
Uniklinik RWTH Aachen
Berlin
Charité Universitaetsmedizin Berlin
Cologne
Universitätsklinikum Köln
Hamburg
Universitaetsklinikum Hamburg-Eppendorf
Jena
Universitätsklinikum Jena
Mannheim
CML Studienzentrale
III. Medizinische Klinik, Universitätsmedizin Mannheim
Italy
Bari
U.O. Ematologia con Trapianto – A.O.U. Policlinico Consorziale
Bologna
A.O.U. Policlinico S. Orsola-Malpighi, U.O. Ematologia
Catania
AOU Policlinico Vittorio Emanuele – P.O. Ferrarotto – UOC Ematologia
Divisione Clinicizzata di Ematologia
Firenze
SOD Ematologia
Milano
Ospedale Niguarda Ca Granda – SC Ematologia
Monza
A.O. San Gerardo – U.O. Ematologia Adulti
Unita Operativa Ematologia Adulti
Napoli
AOU Federico II
Orbassano
AOU San Luigi Gonzaga
Rome
Ospendale S. Eugenio – UOC Ematologia
Udine
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine
Norway
Bergen
Haukeland universitetssjukehus
Trondheim
St Olavs Hospital
Spain
Barcelona
Hospital Clinic I Provincial de Barcelona
Barcelona
Hospital Universitari Vall d’Hebron
Madrid
Hospital Ramon y Cajal
Madrid
Hospital Universitario de La Princesa
Pamplona
Complejo Hospitalario de Navarra Hematologia
Pozuelo De Alacron
Hospital Universitario Quiron Madrid
Salamanca
Clinico Universitario de Salamanca
Valencia
Hospital Universitari i Politecnic La Fe
Zaragoza
Hospital de Dia Quiron Zaragoza
Sweden
Stockholm
Hematologiskt Centrum
Uppsala
Akademiska sjukhuset
USA
California
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles
Keck Hospital of USC, Los Angeles
LAC&USC Medical Center, Los Angeles
Florida
University of Miami Hospital & Clinics, Miami
Indiana
Indiana Blood and Marrow Transplantation-Clinic
Indianapolis
Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Missouri
Washington University School of Medicine, St. Louis
Siteman Cancer Center-West County, Creve Coeur
Siteman Cancer Center-South County, St. Louis
Barnes-Jewish Hospital, St. Louis
New York
Weill Cornell Medical College – Presbyterian Hospital
Washington
Seattle Cancer Care Alliance
Seattle